Acarix

Acarix is a pioneering Swedish medical device company, with an expanding presence in the U.S., transforming cardiac diagnostics with AI-powered acoustic technology. Our flagship solution, the CADScor® System, can rapidly and non-invasively risk stratify Coronary Artery Disease, helping physicians confidently assess chest pain patients while reducing unnecessary, costly, and invasive procedures. With CE-mark approval and FDA De Novo clearance, the CADScor®System provides a patient-specific CAD-score with 96% confidence, streamlining decision-making in both primary and specialized care. Backed by innovation and clinical validation, Acarix is committed to optimizing healthcare efficiency and improving patient care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the U.S. (ticker: ACIXF).